And its at least possible that OCGN could wind up being a winner. Honestly, OCGN stock is unlikely to survive. There's still a chance that the vaccine could receive a green light in Canada. Bharat's offering COVAXIN, a whole-viron inactivated COVID-19 vaccine candidate, has already shown promise in Phase 1 and 2 clinical trials in India and the enrollment of 26,000 subjects for the Phase 3 study is currently underway. The sale of NeoCart, which still is pending, can bring in another $8 million, based on the current agreement. With no effective treatments, and without a clear reason to exist, I would avoid buying Ocugen stock even as a speculative play. The potential synergies of such a union do not seem clear. Maybe OCGN stock will be one of them again. Shares of Ocugen ( OCGN -3.10%) fell on Tuesday after an analyst sounded a note of caution to investors. The S&P 500 has rallied 52.9% from the March low to its highs on August 6. More importantly, the 5-star analyst added, COVAXIN also induces comparable levels of neutralizing antibodies to those in human convalescent serum," which, the analyst believes," bodes well for the success of the ongoing Phase 3 trial in India.. 1125 N. Charles St, Baltimore, MD 21201. The simplest thing to do is to hang onto the stock and hope that it recovers sooner or later (which is a possibility). The stock dropped as low as 26 cents during the height of the pandemic fears in March 2020. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. 2023, Nasdaq, Inc. All Rights Reserved. Ocugen Inc., formerly known as Histogenics Cp, is based in Malvern, Pennsylvania. The stock ultimately hit its 2020 low on June 1 at a price of just 17 cents. Shares of Ocugen ( OCGN) skyrocketed over 800% in the past three trading sessions after the biopharmaceutical company disclosed it had signed a binding letter of intent (LOI) with India based. Ocugen, previously a private company, instituted a reverse merger, which they completed on Sep. 30. (To watch Ramakanths track record, click here), In contrast, all 3 other analysts who have recently posted an Ocugen review rate the stock a Buy. *Stock Advisor returns as of November 20, 2020. Ocugen announced in late Decemberit had signed a letter of intent to co-develop COVID-19 vaccine candidate Covaxin along with Indian pharmaceutical company Bharat Biotech. The biotech stock promptly crashed by more than 30%. Remember, though, that Moderna achieved this while working closely with the U.S. government (including receiving funding from Uncle Sam) and during a period when vaccines weren't widely available. If it goes down, your loss won't be as great as it would be if you held onto all of your shares. ET by MarketWatch Automation Ocugen Inc. stock falls Tuesday, underperforms market Feb. 21, 2023 at 5:14. With $3.2 million in cash vs. current liabilities of $3.3 million, Ocugen likely has enough cash on hand to cover its short-term obligations. It has real products. In December, Ocugen stated that it had put together an advisory board of "leading academic and industry experts to evaluate the clinical and regulatory path to approval in the U.S. Backlinks from other websites are the lifeblood of our site and a primary source of new traffic. InvestorPlace - Stock Market News, Stock Advice & Trading Tips. Shares of Ocugen (OCGN) skyrocketed over 800% in the past three trading sessions after the biopharmaceutical company disclosed it had signed a binding letter of intent (LOI) with India based Bharat Biotech to co-develop a COVID-19 vaccine for the U.S. market. Ocugen stated in a press release that it plans to "continue working with the FDA to evaluate the regulatory pathway for the pediatric use of Covaxin." And a partnership with Chinas CanSino Biologics (OTCMKTS:CASBF) should help the company develop its pipeline. If they have solid financials, but their trials continually fail, they will likely not succeed. The FDA gave a thumbs-down to Ocugen's EUA request for the pediatric use of Covaxin. Weitere Informationen ber die Verwendung Ihrer personenbezogenen Daten finden Sie in unserer Datenschutzerklrung und unserer Cookie-Richtlinie. To be sure, current cash isnt enough. How can we possibly evaluate a stock on a fundamental basis with that being reality? Matt McCall and the InvestorPlace Research Staff, statistics support having long-term exposure, Click here to see what Matt has up his sleeve now, There Are So Many Stocks to Buy Ocugen Isnt One of Them. Matthew McCall left Wall Street toactually helpinvestors by getting them into the worlds biggest, most revolutionary trends BEFORE anyone else. As of this writing, Will Healy did not hold a position in any of the aforementioned stocks. Theres even room for more lines. It is very important to do your own analysis before making any investment. Article printed from InvestorPlace Media, https://investorplace.com/2019/12/no-pathway-forward-for-ocugen-stock/. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return. Guys, theres no revenue here! Keith Speights for Our 3 Top Picks. Shares declined 85% in three sessions around the closing of the merger, which also included a 1-for-60 reverse stock split. OCGN Ocugen Inc 155,223 $0.9721 $0.0263 (2.63%) Article printed from InvestorPlace Media, https://investorplace.com/2020/01/ocugen-stock-faint-heart/. That's not going to happen now. Ocugen Inc. stock rises Wednesday, outperforms market Feb. 22, 2023 at 5:14 p.m. Historical daily share price chart and data for Ocugen since 2023 adjusted for splits. The broad point here is that, even with a ~$30 million market capitalization (based on updated share count information disclosed in an 8-K filing on Dec. 9), this is a company with a legitimate opportunity. David and Tom just revealed what they believe are the ten best stocks for investors to buy right now and Ocugen, Inc. wasn't one of them! For example, after the FDA revised its guidelines for the EUA process for COVID-19 vaccines, Ocugen's CEO stated, "Since we have been in discussions with the FDA since late last year, we do not believe that the FDA's recently revised guidance regarding EUAs raises any concerns about our ability to submit the EUA for Covaxin as planned." Maybe. Create your Watchlist to save your favorite quotes on Nasdaq.com. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return. The vaccine reportedly has a 78% efficacy rate against COVID-19, significantly lower than leading vaccines granted FDA emergency authorization. Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. These options will be cheaper than owning the stock itself. The Motley Fool has no position in any of the stocks mentioned. The short answer is: everything. OCGN does not even appear to have an apparent reason to exist. A bout of buying in late July sent shares from 20 cents apiece to above 90 cents a share a few days later. Still, Ocugens balance sheet isnt as dire as its share price might suggest. Typically, I care little about financials with biotechs. The huge gain came after the company's partner, Bharat Biotech, received emergency use authorization. All rights reserved. We have provided a few examples below that you can copy and paste to your site: Your image export is now complete. Type a symbol or company name. You never know when they will suddenly go on a squeeze. But the allure of the space is that when a company wins, its shareholders win big. The Ocugen deal is a way to salvage some limited value. Just a few days ago, Ocugen (NASDAQ: OCGN) was flying high with shares up more than 460% year to date. Shares fell 72% on the news, and kept falling after Histogenics decided to suspend development of the product in December 2018. However, the Strong Buy consensus rating is backed with a $0.9 price target, which implies downside of 68% from current levels. The FDA typically takes 60 days to accept a regulatory filing then 10 months to make an approval decision. CanSinoBio is a legitimate player in the industry; the companys market cap is near $2 billion after a nice rally in recent weeks. Shares fell 72% on the news, and kept falling after Histogenics decided to suspend development of the product in December 2018. Emergency Use Authorization (EUA) for Covaxin, the COVID-19 vaccine developed by Ocugen's partner, Bharat Biotech. Written by On its first trading day as OCGN stock, it lost almost 64% of its value and closed that day at $2.85 per share. Conditions only seem to get worse for Ocugen (NASDAQ:OCGN). Its certainly possible. Ocugen sold $25 million of stock in a private placement before the merger. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Unfortunately, when the market bounced in late March 2020, Ocugen kept heading lower. At the time, Ocugen was left for dead. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The next key catalyst for the biotech stock could be the announcement of the details of the plan to win EUA for Covaxin in the U.S. market. So, what goes wrong? quotes delayed at least 15 minutes, all others at least 20 minutes. The CanSinoBio partnership does help, but Ocugen still has a long way to go with OCU300. 1 Reason to Buy Ocugen in 2023 and 2 Reasons to Sell, 3 Under-the-Radar Stocks With 590% to 772% Upside in 2023, According to Wall Street, 2 Reasons to Avoid a Roth 401(k) for Your Retirement Savings, Warren Buffett's Latest $2.9 Billion Buy Brings His Total Investment in This Stock to $66 Billion in 4 Years, Want $1 Million in Retirement? The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. 2023, Nasdaq, Inc. All Rights Reserved. I am all for a good opportunity, but I dont know why some investors insist on penny stocks. This can prove to be a costly lesson to learn. For investors new to the story, there are some positives when it comes to OCGN stock. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. For most of its history, what we now know as Ocugen stock was Histogenics, a cell therapy company focused on orthopedics. The Motley Fool has no position in any of the stocks mentioned. Some investors had set their hopes on the FDA being more lenient with pediatric use of Covaxin. Shares of Ocugen (NASDAQ: OCGN) were skyrocketing 64.2% higher as of 11:35 a.m. EST on Monday. Type a symbol or company name. 7 Penny Stocks Poised for Explosive Growth in 2023, With No Revenue or Approved Treatments, Ocugen Stock Is a Clear Sell. Assuming it wins approval for the vaccine, the challenge for the company then will be to achieve commercial success. The second is that the balance sheet still needs some help. Here are three prudent steps to take. The Motley Fool has a disclosure policy. Sign up below to get this incredible offer! MALVERN, Pa., April 28, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness. Nasdaq The company stated that it will pursue a path to file for full FDA approval of Covaxin. Copy and paste multiple symbols separated by spaces. Axsome Therapeutics (NASDAQ:AXSM) had an equity value below $75 million in March 2017; its now worth over $3 billion after rising over 1,000% last year. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. Ramakanth believes the broad immunity targeting different components of the virus could potentially provide better protection against emerging mutant viruses, such as the one currently circulating in the UK. With this in mind, in the Phase 1 study, COVAXIN has shown robust antibody responses against spike (S1) protein, receptor-binding domain (RBD) and the nucleocapsid (N) protein of SARS-CoV-2. Shares of Ocugen (OCGN 4.03%) were crashing 19.2% lower as of 11:23 a.m. As of this writing, Matt did not hold a position in any of theaforementioned securities. The Motley Fool has a disclosure policy. But any success they find will be without me as a shareholder. The huge gain came after the company's partner, Bharat Biotech, received emergency use authorization (EUA) in India for COVID-19 vaccine Covaxin. The equity has experienced a continual decline for years. Copy and paste multiple symbols separated by spaces. Its all about choice. Admittedly one could argue that it could have been bought for a quarter and sold for 75 cents, but hindsight is 20/20 in all of these names. Sign up below to get this incredible offer! market." You canfollow Will on Twitterat @HealyWriting. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The Motley Fool recommends Moderna Inc. The company is led by CEO and Co-founder, Shankar Musunuri, and entered into the public equity market in 2019 via. Written by Some were undoubtedly anticipating a relatively quick EUA win for Covaxin followed by strong U.S. sales for the COVID-19 vaccine. That's right -- they think these 10 stocks are even better buys. It took Moderna roughly 10 months from the initiation of the late-stage study for its COVID-19 vaccine to the point where the company filed for full FDA approval. All rights reserved. The risk-reward proposition for Ocugen is obviously much different now than it was when individuals were buying the stock over the last several months. From a broader perspective, the risk is the same as it is across biotech: most candidates fail. Since its merger, Ocugen stock has continued the decline that occurred under the company that it took over, Histogenics. Ocugen abandoned its pursuit of a U.S. EUA for Covaxin in immunizing adults last year. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA. For now, though, what happens in India stays in India. However, due to the fact the details of the definitive agreement have yet to be finalized, in addition to the current lack of insight into the U.S. regulatory pathway or commercial strategy, Ramakanth stays on the sidelines for now. But theres a big difference in having an edge flipping sub-$5 stocks vs. combing over this group as an investor looking for sound fundamentals and a mistakenly low stock price. The first is that Ocugen is facing potential delisting from the NASDAQ given that its share price still sits well below $1. Source: Chart courtesy of StockCharts.com. Do Not Sell My Personal Information (CA Residents Only). Instead, this appears destined to join the long list of failed biotech startups. To make the world smarter, happier, and richer. Today, the stock has a $1.6 billion market cap despite just $42,620 in 2020 revenue. The Motley Fool->. After encouraging preliminary results, Ocugen began trying to sell 100 million doses of the vaccine in February. Start trading Options with Saxo today. Copyright 2023 InvestorPlace Media, LLC. Maybe it pans out for Ocugen and I wish the team (and its investors) the best of luck. The reverse merger that brought Ocugen to the public markets led to huge losses but some investors are buying the dip. Those reverse splits generally are poorly received by the market, even if in theory they should have little to no practical impact on trading. Instead of buying a piece of the S&P 500 or Nasdaq or even better, a common sense mega-holding like Apple (NASDAQ:AAPL) or Amazon investors in OCGN stock took on a high-risk investment and for months saw negative returns. Concerns about the delta variant, the potential need for annual booster shots and the possibility of expanding the vaccines to children have investors hopeful that Covaxin will still eventually be a huge payoff for Ocugen. As of 1:37 p.m. EST, the biopharmaceutical company's stock price was down more than 15%.. In the late summer of 2018, the stock crashed below $1 per share as investors sold off following a failed phase three trial. The company does not earn revenue, relying on grants, a dwindling cash position, and stock dilution to keep its doors open. Now, with the stock trading near the 40-cent per share level, its prospects have taken a dramatic turn for the worse. 10 stocks we like better than Ocugen, Inc.When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. This requires no immediate effort on your part. Cost basis and return based on previous market day close. Will Be Even Bigger Than Your Wildest Expectation, 7 Over-$100 Stocks That Are Worth Every Penny, Louis Navellier and the InvestorPlace Research Staff, 5 Penny Cryptos With the Most Potential for Growth. One thing seems certain, however:Ocugens fate as an investment is closely tied to the ultimate outcome of Covaxin. As of this writing, Vince Martin has no positions in any securities mentioned. According to the prospectus, the combined company posted an operating loss of roughly $30 million in 2018. As with many biotech stocks, the most likely outcome is for the company to fail, and for shareholders to wind up with zero. It brings in no revenue. Ocugen executives even sounded cautiously optimistic in the company's fourth-quarter conference call last month. Ocugen ( NASDAQ: OCGN) has been one of the more polarizing story stocks of 2021. The point is, the risk/reward of owning something like Ocugen is simply not worth it vs. having even basic equity exposure. The statistics support having long-term exposure to this asset class. Most biotech companies have intriguing stories on paper; Ocugen is no different. 5 Hypergrowth Stocks With 10X Potential in 2023, Robert Bollinger: Meet the Man Behind Mullens Push Into Commercial EVs, A.I. Like Pfizer's BNT162b2 and Moderna's mRNA-1273, it requires two doses. Biotechnology stocks like Ocugen (NASDAQ:OCGN) are among the markets riskiest plays. These symbols will be available throughout the site during your session. Hold) without suggesting a price target. Considering the conditions facing the company, I do not recommend Ocugen stock regardless of risk tolerances. But realizing value in practice usually is a difficult endeavor. 1125 N. Charles St, Baltimore, MD 21201. Until July 20, when OCGN stock jumped about 20%, shares were down 21% from the March low. But just because a company does not have crippling debt doesnt mean its a buy. It means that raising capital will be more difficult going forward. Type a symbol or company name. The stock had gained some traction after they announced the Ocugen merger in April. It has no treatments to offer the market. At the beginning of 2020, Ocugen shares were trading at just 47 cents. How long might it take for Ocugen to win full FDA approval for Covaxin? Making the world smarter, happier, and richer. A bout of buying in late July sent shares from 20 cents apiece to above 90 cents a share a few days. Klicken Sie auf Alle ablehnen, wenn Sie nicht mchten, dass wir und unsere Partner Cookies und personenbezogene Daten fr diese zustzlichen Zwecke verwenden. Literally, zero. This decision. I will just say this on Ocugen: Theres a reason it trades for sub-$1 after hitting resistance near $180 in 2018. All rights reserved. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off. An unprofitable biotech that focused on commercializing therapies to cure blindness prior to the present pandemic, Ocugen ( OCGN) stock took on a new life on December 22, when it announced. If you missed that action, you missed all the gains. Please check your download folder. If OCU300 is approved, theres a reasonably large market. Wenn Sie Ihre Auswahl anpassen mchten, klicken Sie auf Datenschutzeinstellungen verwalten. The FDA's decision not to issue EUA really wasn't all that surprising, though. Copyright 2023 InvestorPlace Media, LLC. The worst news was that another late-stage clinical study will likely be required to support the regulatory filing. Nor should one look forward to OCGN stock to becoming the next GW Pharmaceuticals (NASDAQ:GWPH) or Cara Therapeutics (NASDAQ:CARA). If you use our chart images on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page. It's likely that the company will take longer to file for full FDA approval of the vaccine than Moderna will. That's right -- they think these 10 stocks are even better buys. With No Revenue or Approved Treatments, Ocugen Stock Is a Clear Sell Amryt Pharma releases Q-2 how to setup copy trading labrador gold stock that show strong revenue growth as The first split for NKE took place on October 08, Below, we'll pit these two dominant consumer-discretionary giants against each other, with an eye toward long-term . The stock had gained some traction after they announced the. Still, this stock is cheap for reasons that my colleague Josh Enomoto spelled out well. The average price target among the five analysts covering the stock is $6, suggesting 27.9% downside from current levels. Unfortunately for investors, the U.S. FDA did not grant Covaxin an Emergency Use Authorization and instead recommended in June that Ocugen opt for a Biologic License Application that will likely require additional Phase 3 testing. In 2018, its NeoCart biologic failed to meet the primary endpoint of its own Phase III trial. I will concede this: The one great thing about the stock market is there is a style for everyone. It has real management. Keith Speights owns shares of Pfizer. The company initiated its Phase 3 trial of OCU300 back in July 2018. 1125 N. Charles St, Baltimore, MD 21201. Probably the most important thing to do after Ocugen's crash, though, is to identify lessons learned and apply them to future investing decisions. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return. The latest closing stock price for Ocugen as of March 03, 2023 is. If youre not convinced by now, maybe you will consider OCGN stock a poor investment when looking at the fundamentals. However, I wont be around to find out. Cassava Sciences (NASDAQ:SAVA) has soared 454% in just the last three months. Investors were hopeful that the small drugmaker would be able to win U.S. Even before that point, the most promising candidates generally can find funding. Indeed, the price broke below the 24 December 2018 low at 4.81 and is currently attempting a return move. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. Keith Speights has no position in any of the stocks mentioned. Shares of Ocugen (NASDAQ: OCGN) were skyrocketing 64.2% higher as of 11:35 a.m. EST on Monday. This is most likely a result of the stocks meteoric rise and analysts inability to turnaround new price targets so quickly. David and Tom just revealed what they believe are the ten best stocks for investors to buy right now and Ocugen, Inc. wasn't one of them! Malvern-based biopharmaceutical company Ocugen completed its previously announced $100 million private stock sale. Ocugen Chairman and CEO Shankar Musunuri Ocugen The company's stock opened at $8.24 per share Tuesday, up 96 cents. Without NeoCart, that burn likely comes down. Why Ocugen Stock Is Crashing Today By Keith Speights - Mar 4, 2022 at 11:42AM Key Points The FDA gave a thumbs-down to Ocugen's EUA request for the pediatric use of Covaxin. From the outside looking inward, it looks like a marriage of two people who got together simply because nobody else would take them. OCU300 already has received an orphan drug designation from the U.S. Food & Drug Administration for oGVHD; there is no currently approved treatment in the U.S. Long-term debt of $1.6 million is not a back-breaker either. Theres an opportunity here. There's no way, however, to know what the COVID-19 vaccine market dynamics will be two years from now. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. However, even from this limited vantage point, OCGN appears destined to fail. The post There Are So Many Stocks to Buy Ocugen Isnt One of Them appeared first on InvestorPlace. Considering Bharats reputation for world-class R&D and manufacturing capabilities in vaccines and bio-therapeutics, H.C. Wainwright analyst Swayampakula Ramakanth thinks the company is a suitable partner.. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide. Ocugen hasn't stated yet when a potential late-stage study of Covaxin could start. 2023 InvestorPlace Media, LLC. The content is intended to be used for informational purposes only. Thats the thing with these low-priced penny stocks. The company has a gene therapy platform as well as two preclinical compounds that aim to treat retinal diseases. If they invent a miracle treatment for a condition, the money will find its way to the stock. It is focused on discovering, developing and commercializing therapies which address rare and underserved eye diseases. The generic form of brimonidine, the active ingredient, is not approved for the condition, according to Ocugens most recent presentation. The Motley Fool has a disclosure policy. Create your Watchlist to save your favorite quotes on Nasdaq.com. 5 Hypergrowth Stocks With 10X Potential in 2023, Robert Bollinger: Meet the Man Behind Mullens Push Into Commercial EVs, A.I. Still, Ocugen investors who bought one year ago and held on have generated a huge return on their investment. OCGN | Ocugen Inc. Stock Price & News - WSJ Ocugen Inc. OCGN (U.S.: Nasdaq) REAL TIME 12:30 PM EST 02/21/23 $0.9819USD -0.0981 -9.08% Volume 3,761,699 65 Day Avg Vol 5,026,332 1 Day Range. Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. Objective investors could have clearly seen then that there actually were significant reasons to be concerned. COVID-19 vaccines from Pfizer and Moderna are already on the market in the U.S. with efficacy levels of 94% or greater. A partnership with a respected Asian biotechnology company offers some validation to the pipeline, and a key product is progressing through Phase III trials. Ocugen Inc Stock - OCGN Share Price Today, News and Discussion 0.90% SPY 0.59% QQQ 0.60% TSLA 6.12% SI 60.35% CRM 11.51% RIVN 0.32% ARKK 0.96% RLY.X 56.44% PLUG 6.72% V 0.22% CDIO 13.87% RETA 5.92% More Advertisement 3rd Party Ad. The company's product pipeline consists of OCU400, OCU300, OCU100 and OCU200 which are in clinical stage. Conditions have only become worse since that time. You could sell some or all of your Ocugen shares and buy long-term call options on the stock. Investors appear to expect that Bharat's big win for Covaxin in India could translate to success for Ocugen in the U.S. On Dec. 22, Ocugen and Bharat announced a binding letter of intent to jointly develop Covaxin for the U.S. market. The median estimate. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The combined company has an agreement to sell the rights to NeoCart to privately held Medavate, leaving it reliant on Ocugens pipeline. Ocugen estimates the drug could have as many as 63,000 potential patients. Stock Price Forecast The 6 analysts offering 12-month price forecasts for Ocugen Inc have a median target of 4.75, with a high estimate of 8.00 and a low estimate of 3.00. The Motley Fool->. Healthy companies do not undergo 1-for-60 reverse stock splits like this one did in September 2019. You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com. Invest better with The Motley Fool. CanSinoBio will be able to fund much of the development of OCU300, Ocugens flagship product that targets oGVHD (ocular graft versus host disease), a common complication of bone marrow transplants.
Distance From St George Utah To Reno Nevada, Amy Theismann Obituary, $1 Dollar In 1865 Worth Today, Articles O
Distance From St George Utah To Reno Nevada, Amy Theismann Obituary, $1 Dollar In 1865 Worth Today, Articles O